leadf
logo-loader
viewAstraZeneca

AstraZeneca lung cancer drug receives US regulatory green light

Tagrisso will be used to target the early-stage epidermal growth factor receptor-mutated form of the disease

AstraZeneca -

The US regulator has given the AstraZeneca PLC (LON:AZN) drug Tagrisso the green light to be used in people with non-small cell lung cancer that have undergone surgery.

It will be given as an adjuvant - which means it will be administered in addition to the initial treatment. And it will be used to target the early-stage epidermal growth factor receptor-mutated (EGFR) form of the disease “with curative intent”.

"For the first time, a targeted, biomarker-driven treatment option is available to patients in the US with early-stage EGFR-mutated lung cancer,” said Dave Fredrickson, vice president of AstraZeneca’s oncology business unit in a statement.

“This approval dispels the notion that treatment is over after surgery and chemotherapy, as the ADAURA phase III clinical trial results show that Tagrisso can dramatically change the course of this disease. We remain committed to treating cancer patients earlier, when they may still have a chance of being cured."

In a separate announcement, AstraZeneca also said the US Food and Drug Administration has requested “further clarifying analyses of clinical data” before considering whether to approve Roxadustat, a drug for people with anaemia from chronic kidney disease.

Quick facts: AstraZeneca

Price: 7047 GBX

LSE:AZN
Market: LSE
Market Cap: £92.47 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Scotgold Resources' CEO Richard Gray set to retire as mine goes from...

Scotgold PLC’s (LON:SGZ) chief executive Richard Gray and Philip Day tell our Proactive audience about the news of Gray's retirement at the end of March following the group’s move from an explorer to producer. Gray says 'the basics are now in place and we look forward to adding new value under...

3 minutes ago

2 min read